<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274025</url>
  </required_header>
  <id_info>
    <org_study_id>TISS001</org_study_id>
    <nct_id>NCT02274025</nct_id>
  </id_info>
  <brief_title>NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients</brief_title>
  <official_title>Collection of Lung Malignant Tissue for the Validation of a Novel Technology to Identify Oncogenic Mutations and Personalized Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovellusDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovellusDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NovellusDx technology identifies tumor-specific driver mutations, but unlike
      sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated
      translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to
      identify functionally-impactful driver mutations regardless of whether the mutation has
      previously been described or linked to a tumor type.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Correct identification of tumor mutant genes</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Correct identification of patient oncogenic mutation in over 85% of the cases. this will be achieved by comparing sequencing results of the patient tumors to the results achieved using the NovellusDx diagnostic platform.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy material of patient or pleural fluids.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that are suspected to have lung cancer and are eligible for biopsy, surgical
        intervention or pleural fluid suction.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that are suspected to have lung cancer and are eligible for biopsy, surgical
             intervention or pleural fluid suction

        Exclusion Criteria:

          -  Patients without lung cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mordechai Kremer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center, Beilinson</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabi Tarcic, PhD</last_name>
    <phone>972-2-5001100</phone>
    <email>gabi@novellusdx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 6, 2015</lastchanged_date>
  <firstreceived_date>October 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient diagnosed with lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
